Characterisation of an influenza B virus-derived peptide presented by HLA-B*18:01
Biochemical Journal · 2025
DOI: 10.1042/bcj20240739 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Journal, 2025. Verfasst von Lawton D Murdolo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Infection and Immunity Program, La Trobe Institute for Molecular Science (LIMS), Victoria, Bundoora VIC, Australia. Hauptthemen laut MEDLINE: Influenza B virus, HLA-B Antigens, Peptides, Antigen Presentation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: La Trobe University (LTU), Australian Institute of Nuclear Science and Engineering (AINSE), Department of Education and Training | Australian Research Council (ARC).
Abstract (Originalsprache)
The influenza B virus (IBV) can pose a significant threat to global health. Despite this, IBV is understudied compared with influenza A virus (IAV). CD8+ T cells have proven highly effective in reducing influenza disease severity. In addition, pre-existing immune responses towards IAV epitopes may provide protection against homologous IBV-derived peptides due to T cell cross-reactivity. To exploit the advantages of T cells for future vaccine developments, a better understanding of the IBV-derived peptide presentation by the highly polymorphic human leukocyte antigen (HLA) is required. We previously determined that the IAV-derived PB1177-A peptide was presented by the HLA-B*18:01 molecule and induced CD8+ T cell responses. Here, we assessed the PB1177-A IBV homologue (PB1177-B). Intracellular cytokine staining assays showed that PB1177-B was unable to activate CD8+ T cells from several HLA-B*18:01+ samples tested. We determined that the IAVand IBV-derived PB1177 adopted different stability and conformation in the cleft of HLA-B*18:01. Molecular dynamics analysis on the crystal structure showed that PB1177-B had a central flexible region with a large hydrophobic patch formed by two phenylalanine residues, not present in PB1177-A. The flexibility and the lower stability of the HLA-B*18:01-PB1177-B complex may hinder CD8+ T cell receptor binding, underpinning the lack of CD8+ T cell activation observed. This provides additional insights into the differences between IAVand IBV-specific CD8+ T cell responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infection and Immunity Program, La Trobe Institute for Molecular Science (LIMS), Victoria, Bundoora VIC, Australia.
- Department of Biochemistry and Chemistry, La Trobe University, Victoria, Bundoora VIC, Australia.
- Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
- Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.
ORCID-Profile: Stephanie Gras
Förderung
- La Trobe University (LTU)
- Australian Institute of Nuclear Science and Engineering (AINSE)
- Department of Education and Training | Australian Research Council (ARC)
- DHAC | National Health and Medical Research Council (NHMRC)
Zitieren
APA
Murdolo, L. D., Liwei Leong, S., Maddumage, J. C., Mifsud, N. A., Chatzileontiadou, D. S. M., Grant, E. J., & Gras, S. (2025). Characterisation of an influenza B virus-derived peptide presented by HLA-B*18:01. Biochemical Journal. https://doi.org/10.1042/bcj20240739
Vancouver
Murdolo LD, Liwei Leong S, Maddumage JC, Mifsud NA, Chatzileontiadou DSM, Grant EJ, et al. Characterisation of an influenza B virus-derived peptide presented by HLA-B*18:01. Biochemical Journal. 2025. doi:10.1042/bcj20240739
BibTeX
@article{Murdolo2025,
author = {Murdolo, Lawton D and Liwei Leong, Samuel and Maddumage, Janesha C and Mifsud, Nicole A and Chatzileontiadou, Demetra S M and Grant, Emma J and Gras, Stephanie},
title = {Characterisation of an influenza B virus-derived peptide presented by HLA-B*18:01},
journal = {Biochemical Journal},
year = {2025},
doi = {10.1042/bcj20240739}
}
EUVIMED